Research and Markets: Chemotherapy Induced Neutropenia - Pipeline Review & Analysis H2 2015
November 27 2015 - 8:04PM
Business Wire
Research and Markets
(http://www.researchandmarkets.com/research/j84hq9/chemotherapy)
has announced the addition of the "Chemotherapy Induced Neutropenia
- Pipeline Review, H2 2015" report to their offering.
The report, Chemotherapy Induced Neutropenia - Pipeline Review,
H2 2015, provides an overview of the Chemotherapy Induced
Neutropenia's therapeutic pipeline.
This report provides comprehensive information on the
therapeutic development for Chemotherapy Induced Neutropenia,
complete with comparative analysis at various stages, therapeutics
assessment by drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type, along with latest updates,
and featured news and press releases.
Key Topics Covered:
- Snapshot of the global therapeutic landscape of Chemotherapy
Induced Neutropenia
- Key pipeline products under drug profile section which includes
product description, MoA and R&D brief, licensing and
collaboration details & other developmental activities
- Key players involved in the therapeutics development for
Chemotherapy Induced Neutropenia and enlists all their major and
minor projects
- All dormant and discontinued pipeline projects
- Chemotherapy Induced Neutropenia products under development by
companies and universities/research institutes based on information
derived from company and industry-specific sources
- Pipeline products coverage based on various stages of
development ranging from pre-registration till discovery and
undisclosed stages
- Detailed assessment of monotherapy and combination therapy
pipeline projects
- Coverage of the Chemotherapy Induced Neutropenia pipeline on
the basis of target, MoA, route of administration and molecule
type
- Latest news and deals relating related to pipeline
products
Benefits of this Report:
- Provides strategically significant competitor information,
analysis, and insights to formulate effective R&D development
strategies
- Identify emerging players with potentially strong product
portfolio and create effective counter-strategies to gain
competitive advantage
- Develop strategic initiatives by understanding the focus areas
of leading companies
- Identify and understand important and diverse types of
therapeutics under development for Chemotherapy Induced
Neutropenia
- Plan mergers and acquisitions effectively by identifying key
players of the most promising pipeline
- Devise corrective measures for pipeline projects by
understanding Chemotherapy Induced Neutropenia pipeline depth and
focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects
to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued
projects and understanding the factors that drove them from
pipeline
Companies Mentioned:
- Apotex, Inc.
- Biogenomics Limited
- Bolder Biotechnology, Inc.
- Cellerant Therapeutics, Inc.
- Chong Kun Dang Pharmaceutical Corp.
- Dr. Reddy's Laboratories Limited
- Generon (Shanghai) Corporation Ltd.
- Genexine, Inc.
- Hanmi Pharmaceuticals, Co. Ltd.
- Hospira, Inc.
- Myelo Therapeutics GmbH
- Octapharma AG
- Pfenex Inc.
- Pfizer Inc.
- PharmaEssentia Corporation
- Reliance Life Sciences Pvt. Ltd.
- Richter Gedeon Nyrt.
- Sandoz International GmbH
- UAB Profarma
- USV Limited
- Welichem Biotech Inc.
For more information visit
http://www.researchandmarkets.com/research/j84hq9/chemotherapy
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151127005404/en/
Research and MarketsLaura Wood, Senior
Managerpress@researchandmarkets.comFor E.S.T Office Hours Call
1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT
Office Hours Call +353-1-416-8900U.S. Fax: 646-607-1907Fax (outside
U.S.): +353-1-481-1716Sector: Oncology